Member Info for ROCKZ

Sang, I sense a change in your mood on TILS. Are you back in or something?

70p lol, good luck with that, it’s going the other way.

Listen from 37 mins 30s until 40 mins 30s.
Gabrielle confirms that they are trying to launch Phase 2 Covid trial at the moment and results are expected before the year ends.
He also confirms that the Crohns trial is due to start in the next couple of months aswell.
The interview was two weeks ago so expecting news to drop anytime within the next 6 weeks.
https://audioboom.com/posts/7872243-traders-cafe-with-zak-mir-sunday-roast-extra-may-23rd

MS is long term dosing of Foralumab.
Covid is short term dosing of Foralumab.
That’s the way I understand it and that’s why I am expecting news of a trial start date sooner rather than later.

Proof of concept results for a potential blockbuster drug within under 7 months from here.
It’s not exactly a tough hold from here for large gains.

Roker, the near term catalysts are the next stage of Foralumab trials for Covid (nasally) and Crohns (orally).

I’m not sure the company would have been able to raise the $57 million as easily without Covid.
A terrible event for many families for which I sympathise but you have to play the market which the BOD have done well.
Some investors here are yet to bear fruit but the company is looking in a strong position both cash and pipeline wise.
Excellent buying opportunity still at these levels IMO and I expect to see progress in the SP shortly.

I hope they check the IP address of the muppet who was calling it a scam over on Stocktwits.

You haven’t really lost much money if you buy back in tomorrow morning at these low levels.
Other than that, cut your losses and move on.

Thanks for sharing Paul. Time for the SP to do it’s bit now! STRONG BUY/HOLD

Morning James.

The MAB market is growing and the neurological degeneration area is the next big move.
What Gabrielle was saying on the Sunday roast about the FDA being ultra cautious to MAB’s seems to be playing out, see article.
https://www.evaluate.com/node/16900/amp

Tiziana have got some serious disruptive tech on their hands here.
The cost saving for monoclonal antibodies by using an oral or nasal form of administration instead of IV or sub cutaneous is off the scale! $$$$$$$$$
Which big pharmaceutical company will blink first and how far down the trial path will they wait before making their move?

Foralumab ‘the jewel in the crown’ is working its magic again’.

KS is so much more comfortable talking about the science and Foralumab especially. Get the impression it has become his baby and could be a huge legacy maker for him, probably bigger than we all think.
StemprintER/Accustem is obviously GC’s baby and pretty obvious that Kunwar didn’t want to get involved in that discussion. He even said he wasn’t happy in how it had been handled.

Sang, maybe you should post this on the 4D pharma board and make investors aware:
https://www.investorlawyers.com/blog/amp/triad-advisors-gpb-capital-investor-claims/

Quiet today because the chief investor of 4D is constantly on the TILS BB ****ging off that share lol

Anything happening at 4D Pharma today or all rosey? Snooze

HC Wainwright valuation of StemprintER and spare as a company was $280 million.
By the time it IPO’s the new company structure will be a lot stronger by the sound of what GC was saying and he is keen to bring onboard individuals with knowledge of the prognostic markets.
Accustem will also look to grow as a company and will not be reliant on StemprintER/Spare only.

Good to see SNG move today on that RNS.
I say that because TILS often seems to track behind SNG by approximately 30 percent. I don’t expect to see that straight away but maybe that gap will return again over the next couple of weeks.
I could be totally wrong and it’s just something I’ve noticed.
Added £2000 more for good measure at 74.77p. Looking undervalued at these levels to me and GC knows it more than anyone, as his interview showed yesterday.